Lexicon Pharmaceuticals, Inc.
LXRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001062822
In the last 90 days, Lexicon Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 150 institutions reported holding it in 13F filings for Q2 2026, worth $875.1M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $797.0M
- Insider buysLast 90 days, $50.0K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +14 vs. previous quarter
- 150
- 13F valueReported value at the end of Q2 2026
- $875.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $49.8M
- +60.2% year over year
- Net income, FY2025
- -$50.3M
- No comparable prior period
- Free cash flow, FY2025
- -$67.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $11.3M
- −20.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $50.3M (101.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 25.9M
- Shares sold short
- Change
- −826.0K
- −3.1% vs. previous
- Days to cover
- 14.04
- At average daily volume
Superinvestors holding LXRX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding LXRX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Lexicon Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 9, 2026 (view filing)8:13 AM ET | Nov 6 | 3 days | Exton MichaelChief Executive Officer | PPurchase | +30.1K | $1.66 | +$50.0K | +10.1%328.5K after | |
| Feb 27, 2026 (view filing) | Feb 25 | 2 days | Debbane RaymondDirector | PPurchase | +2.00K | $1.49 | +$2.98K | +0.1%1.91M after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Debbane RaymondDirector | PPurchase | +100.0K | $1.47 | +$147.0K | +5.5%1.90M after | |
| Feb 23, 2026 (view filing) | Feb 19-20 | 4 days | Debbane RaymondDirector | PPurchase | +150.0K | $1.47 | +$220.0K | +9.1%1.80M after | 2 lots |
| Feb 18, 2026 (view filing) | Feb 13-18 | 5 days | Debbane RaymondDirector | PPurchase | +268.5K | $1.31 | +$353.1K | +19.4%1.65M after | 3 lots |
| Feb 4, 2026 (view filing)4:25 PM ET | Feb 2 | 2 days | Debbane Raymond and 8 othersDirector | PPurchase | +1.54M | $1.30 | +$2.00M | New position1.54M after | |
| Nov 17, 2023 (view filing) | Nov 16 | 1 day | Coats LonnelChief Executive Officer | PPurchase | +90.0K | $1.05 | +$94.5K | +10.9%914.4K after | |
| Nov 14, 2023 (view filing) | Nov 13 | 1 day | Amouyal PhilippeDirector | PPurchase | +200.0K | $1.01 | +$202.0K | +495.9%240.3K after | |
| Nov 13, 2023 (view filing) | Nov 10 | 3 days | Coats LonnelChief Executive Officer | PPurchase | +10.0K | $1.01 | +$10.1K | +1.2%824.4K after | |
| Oct 12, 2023 (view filing) | Oct 10-12 | 2 days | Debbane RaymondDirector | PPurchase | +1.00M | $1.10 | +$1.10M | +293.4%1.34M after | 3 lots |
Top 10 13F holders, Q2 2026
See all 150 holdersThe largest institutional positions in Lexicon Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Artal Group S.A. | 175,156,062 | $420.4M | 45.15% | +20,421,735+13.2% | Added |
| FMR LLC | 51,782,045 | $124.3M | 0.01% | +6,725,707+14.9% | Added |
| Siren, L.L.C. | 44,303,518 | $106.3M | 2.16% | 00.0% | Unchanged |
| Sessa Capital IM, L.P. | 18,960,836 | $45.5M | 0.79% | +1,047,875+5.8% | Added |
| BlackRock, Inc. | 17,348,741 | $41.6M | 0.00% | +14,026,522+422.2% | Added |
| Vanguard Capital Management LLC | 9,901,208 | $23.8M | 0.00% | +382,041+4.0% | Added |
| Point72 Asset Management, L.P. | 8,251,325 | $19.8M | 0.03% | +436,719+5.6% | Added |
| Geode Capital Management, LLC | 6,244,372 | $15.0M | 0.00% | +3,075,261+97.0% | Added |
| State Street Corp | 4,917,769 | $11.8M | 0.00% | +3,953,731+410.1% | Added |
| Vanguard Portfolio Management LLC | 2,357,749 | $5.66M | 0.00% | +1,811,149+331.3% | Added |
Holders of 5% or more of LXRX
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Lexicon Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Invus Global Management, LLC | 13D/A | 39.40%175.2M shares | +3.20 ppfrom 36.20% | Feb 2, 20262 filings | May 8, 2026 | SEC |
| FMR LLC | 13G/A | 15.00%66.7M shares | +3.30 ppfrom 11.70% | Jan 11, 20218 filings | Nov 5, 2026 | SEC |